High phosphorous intake associated with increased risk of lethal prostate cancer
the ONA take:
According to a new study published in the American Journal of Clinical Nutrition, phosphorous is independently associated with the risk of developing lethal and high-grade prostate cancer.
Researchers identified nearly 48,000 men who reported their diet in 1986 and every 4 years thereafter. During the 24-year follow-up, 5,861 participants developed prostate cancer, 789 of which were lethal cancers. Results showed phosphorous intake was linked with a greater risk for developing prostate cancer, including lethal and high-grade disease.
This association was independent of calcium and dairy, fish, red meat, and white meat intake. In addition, high calcium intake was associated with an elevated risk for developing advanced-stage and high-grade disease 12 to 16 years after exposure.
High phosphorous intake was linked with an increased risk for developing advanced-stage and high-grade prostate cancer 0 to 8 years after exposure. Foods high in phosphorous include: seeds, lentils, cheese, colas, shellfish, and yogurt.
Phosphorous is independently associated with the risk of developing lethal and high-grade prostate cancer.
- Blood Test Predicts Stem Cell Transplant Success in Myelodysplastic Syndrome
- Immunotherapy and the Future of Prostate Cancer Treatment
- Elderly with NSCLC Can Tolerate Aggressive Radiation Therapy Treatments
- E-cigarettes and Replacement Nicotine Therapy Safer Than Tobacco Use
- Patients With Urologic Cancer Need Psycho-oncologic Support to Manage High Stress
- Lung Cancer Screening Rates Low Among Present and Former Smokers
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- Patients Undergoing Multiple Systemic Therapies for Metastatic Prostate Cancer Expect a Cure
- FDA Grants Priority Review to Ceritinib for First-line Treatment of ALK+ NSCLC
- Overall Health Worse in African American Men Undergoing Active Surveillance For Prostate Cancer
- Clinical Benefit of Simtuzumab Inconsistent for Myelofibrosis
- Follow-up Rates in Active Surveillance for Prostate Cancer Higher in University-Based vs Safety-Net Hospitals
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|